OR WAIT 15 SECS
Under the restructuring, Sanofi will gain sole global rights to Kevzara (sarilumab) and sole ex-US rights to Praluent (alirocumab), while Regeneron will gain sole US rights to Praluent.
On Dec. 10, 2019, Sanofi and Regeneron Pharmaceuticals announced their intent to simplify their antibody collaboration for the Praluent (alirocumab) and Kevzara (sarilumab) antibodies by restructuring into a royalty-based agreement. In 2018, Praluent, for treating high cholesterol, had EUR 261 million (US$290 million) in sales and Kevzara, for treating rheumatoid arthritis, had EUR 83 million (US$92 million).
Under the proposed restructuring, Sanofi is expected to gain sole global rights to Kevzara and sole ex-United States rights to Praluent. Regeneron is expected to gain sole US rights to Praluent. Under the agreement, each party will be solely responsible for funding development and commercialization expenses in their respective territories. Completion of the proposed agreement is expected to be finalized in the first quarter of 2020.
These changes are expected to increase efficiency and streamline operations for the products. The existing collaboration relating to Dupixent (dupilumab) will remain unchanged following the restructuring.